JPH07505529A - プローブ構成物および方法 - Google Patents
プローブ構成物および方法Info
- Publication number
- JPH07505529A JPH07505529A JP5517681A JP51768193A JPH07505529A JP H07505529 A JPH07505529 A JP H07505529A JP 5517681 A JP5517681 A JP 5517681A JP 51768193 A JP51768193 A JP 51768193A JP H07505529 A JPH07505529 A JP H07505529A
- Authority
- JP
- Japan
- Prior art keywords
- probe
- sequence
- target
- polymer
- probes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000523 sample Substances 0.000 title claims description 442
- 238000000034 method Methods 0.000 title claims description 141
- 239000000203 mixture Substances 0.000 title claims description 34
- 229920000642 polymer Polymers 0.000 claims description 238
- 102000040430 polynucleotide Human genes 0.000 claims description 147
- 108091033319 polynucleotide Proteins 0.000 claims description 147
- 239000002157 polynucleotide Substances 0.000 claims description 147
- 108091034117 Oligonucleotide Proteins 0.000 claims description 112
- 239000012634 fragment Substances 0.000 claims description 90
- 108020004414 DNA Proteins 0.000 claims description 61
- 230000027455 binding Effects 0.000 claims description 58
- 238000006243 chemical reaction Methods 0.000 claims description 50
- 125000003729 nucleotide group Chemical group 0.000 claims description 45
- 239000002773 nucleotide Substances 0.000 claims description 44
- 238000001962 electrophoresis Methods 0.000 claims description 40
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 39
- 238000009396 hybridization Methods 0.000 claims description 31
- 230000000295 complement effect Effects 0.000 claims description 29
- 230000003321 amplification Effects 0.000 claims description 18
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- 102000053602 DNA Human genes 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 6
- 230000000869 mutational effect Effects 0.000 claims description 5
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 238000006116 polymerization reaction Methods 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 238000003795 desorption Methods 0.000 claims 1
- 238000005868 electrolysis reaction Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000013615 primer Substances 0.000 description 50
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000002609 medium Substances 0.000 description 22
- 239000000047 product Substances 0.000 description 20
- 238000000926 separation method Methods 0.000 description 19
- 238000005251 capillar electrophoresis Methods 0.000 description 17
- 230000035772 mutation Effects 0.000 description 17
- -1 polyethylene Polymers 0.000 description 17
- 235000011178 triphosphate Nutrition 0.000 description 14
- 239000001226 triphosphate Substances 0.000 description 14
- 150000008300 phosphoramidites Chemical class 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 238000007834 ligase chain reaction Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 238000010168 coupling process Methods 0.000 description 11
- 239000000975 dye Substances 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 239000002777 nucleoside Substances 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 238000001712 DNA sequencing Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000007850 fluorescent dye Substances 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 description 5
- 125000003944 tolyl group Chemical group 0.000 description 5
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 210000003323 beak Anatomy 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 4
- 239000002751 oligonucleotide probe Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 239000005546 dideoxynucleotide Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical group CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 2
- OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- QRMKTNANRJCRCY-UHFFFAOYSA-N ethylammonium acetate Chemical compound CC[NH3+].CC([O-])=O QRMKTNANRJCRCY-UHFFFAOYSA-N 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000017525 heat dissipation Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229960000523 zalcitabine Drugs 0.000 description 2
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- IOHJQSFEAYDZGF-UHFFFAOYSA-N 2-dodecyloxirane Chemical compound CCCCCCCCCCCCC1CO1 IOHJQSFEAYDZGF-UHFFFAOYSA-N 0.000 description 1
- APYLVKKFBMCJNQ-UHFFFAOYSA-N 4-[[di(propan-2-yl)amino]-dihydroxy-propan-2-yl-lambda5-phosphanyl]-4-methylpentanenitrile Chemical compound CC(C)N(C(C)C)P(C(C)C)(C(C)(C)CCC#N)(O)O APYLVKKFBMCJNQ-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 108010063905 Ampligase Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000272165 Charadriidae Species 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101710161955 Mannitol-specific phosphotransferase enzyme IIA component Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 206010048669 Terminal state Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- TUXOBALMXBTRPP-UHFFFAOYSA-N acetic acid;n,n-diethylethanamine;hydrate Chemical compound O.CC([O-])=O.CC[NH+](CC)CC TUXOBALMXBTRPP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SAIKDASRPDRSGZ-UHFFFAOYSA-O di(propan-2-yl)azanium;1,2,3-triaza-4-azanidacyclopenta-2,5-diene Chemical class C1=NN=N[N-]1.CC(C)[NH2+]C(C)C SAIKDASRPDRSGZ-UHFFFAOYSA-O 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZLRAAUUPULJGTL-UHFFFAOYSA-N diaminophosphinous acid Chemical compound NP(N)O ZLRAAUUPULJGTL-UHFFFAOYSA-N 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- CIXHNHBHWVDBGQ-UHFFFAOYSA-N n-propan-2-ylpropan-2-amine;2h-tetrazole Chemical compound C1=NN=NN1.CC(C)NC(C)C CIXHNHBHWVDBGQ-UHFFFAOYSA-N 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- ORQBXQOJMQIAOY-UHFFFAOYSA-N nobelium Chemical compound [No] ORQBXQOJMQIAOY-UHFFFAOYSA-N 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- QZRXRMPNCPCMSW-UHFFFAOYSA-N phosphanyl(phosphanylidene)phosphane Chemical compound PP=P QZRXRMPNCPCMSW-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6862—Ligase chain reaction [LCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (18)
- 1.1またはそれ以上の異なるシーケンスのポリヌクレオチドを形成し、各異な るシーケンスのポリヌクレオチドは(i)検出できるレポーター標識および(i i)各異なるシーケンスのポリヌクレオチドに電荷/並進摩擦抵抗の特有の比を 分与する結合ポリマー鎖を含み、 前記ポリヌクレオチドを、篩分けしていないマトリックス中でキャピラリー電気 泳動によって分別し、そして 分別したポリヌクレオチドを検出する 工程から成る、篩分けしていない媒体中で電気泳動により異なるシーケンスのポ リヌクレオチドを識別する方法。
- 2.ポリマー鎖が実質的に同じ長さであり、前記異なるシーケンスのポリヌクレ オチドが異なる長さである、請求項1の方法。
- 3.DNAをジデオキシ鎖終結によって配列決定するため、前記ポリヌクレオチ ドを前記ポリマー鎖が共有結合している5′−プライマーを用いて形成する、請 求項2の方法。
- 4.各異なるシーケンスのポリヌクレオチドの3′−末端ヌクレオチドを識別す るために有効なスペクトルにより解像できる染料で共役的に標識を付けるジデオ キシヌクレオチドで3′−末端にて、前記異なるシーケンスのポリヌクレオチド が終結する、請求項3の方法。
- 5.試料中の1またはそれ以上の標的シーケンスを検出するために、前記形成す る工程が、 1またはそれ以上の異なるシーケンスプローブを用意し、各異なるシーケンスプ ローブが(i)検出できるレポーター標識および(ii)各異なるシーケンスの ポリヌクレオチドに電荷/並進摩擦抵抗の特有の比を分与する結合ポリマー鎖を 含み、 前記プローブと標的ポリヌクレオチドとを、標的ポリヌクレオチドとシーケンス 相補的プローブとがハイブリッド形成するために有効な条件下に反応させ、そこ では標的ポリヌクレオチドは前記反応の前または後に固体支持体上に固定化され ており、 固定化した標的ポリヌクレオチドを洗浄してシーケンス特異的方法で標的ポリヌ クレオチドに結合していないプローブを除去し、そして標的ポリヌクレオチドを 変性して標的ポリヌクレオチドにハイブリッド形成した異なるシーケンスのプロ ーブを脱離し、電気泳動による分離のための異なるシーケンスのポリヌクレオチ ドを形成する各工程から成る、請求項1の方法。
- 6.前記異なるシーケンスのプローブが実質的に同じ長さである、請求項5の方 法。
- 7.試料中の1またはそれ以上の標的シーケンスを検出するために、前記形成す る工程が、(i)標的ポリヌクレオチドに1またはそれ以上のシーケンス特異的 プローブを付加し、各プローブが、標的シーケンス中の隣接領域に結合するため に有効である第1と第2のプローブオリゴヌクレオチドを有し、そして前記第1 と第2のプローブオリゴヌクレオチドは前記ポリマー鎖で誘導化され、(ii) プローブを標的ポリヌクレオチドと、各プローブ中で前記第1と第2のプローブ オリゴヌクレオチドをそれらの特異的標的シーケンスに結合するために有効な条 件下に反応させ、(iii)標的ポリヌクレオチドに結合した前記オリゴヌクレ オチドを、それらの末端サブユニットが隣接する標的塩基と塩基対になっている とき標的結合オリゴヌクレオチドの夫端サブユニットを連結するために有効な条 件下に連結させ、連結したプローブを形成し、そして(iv)連結したプローブ を標的ポリヌクレオチドから脱離して前記異なるシーケンスのポリヌクレオチド を形成する工程を含む、請求項1の方法。
- 8.前記ポリマー鎖が前記第1のプローブオリゴヌクレオチドに共役結合してお り、そして各前記第2のプローブオリゴヌクレオチドがレポーター標識を付けて いる、請求項7の方法。
- 9.前記脱離前に、前記連結したプローブをプローブ結合および連結反応の繰り 返しのサイクルによって増幅する、請求項7の方法。
- 10.各プローブ中の第2のプローブオリゴヌクレオチドが、(i)会合した標 的シーケンスの同じ位置において代替シーケンスに相補的であり、そして(ii )異なる検出できるレポーターで誘導化される2つの代替シーケンスオリゴヌク レオチドを含み、そして前記検出工程が(a)プローブと会合した標的シーケン スを同定する各プローブのサイン電気泳動移動度、および(b)標的シーケンス の突然変異状態を同定するサインレポーター部分に従って、各前記標的シーケン スの突然変異状態を決定することを含む、請求項7の方法。
- 11.試料中の1またはそれ以上の標的シーケンスを検出するために、前記形成 する工程が、(i)標的ポリヌクレオチドに1またはそれ以上のシーケンス特異 的プローブを付加し、各プローブは、それぞれ、標的ポリヌクレオチド断片の相 補的鎖の向い合った末端領域でハイブリッド形成するために有効な第1と第2の シーケンス特異的プライマーオリゴヌクレオチドを有し、そこでは各プローブ中 の第1のプライマーオリゴヌクレオチドがプローブ特異的ポリマー鎖で誘導化さ れ、(ii)プローブを標的ポリヌクレオチドと、標的ポリヌクレオチドの相補 的鎖の向い合った未婚領域に両方のプライマーオリゴヌクレオチドを結合するた めに有効な条件下に反応させ、そして(iii)プライマー開始ポリメラーゼ鎖 反応によって標的断片を増幅し、異なるシーケンスのポリヌクレオチドを形成す る工程を含む、請求項1の方法。
- 12.各前記第2のプライマーオリゴヌクレオチドがレポーター標識を付け、そ して前記異なるシーケンスのポリヌクレオチドが2本鎖である、請求項11の方 法。
- 13.前記形成する工程が、(i)標的ポリヌクレオチドに1またはそれ以上の シーケンス特異的プローブを付加し、各プローブは、第1の1本鎖DNA断片お よび1本鎖RNAを含む第2の断片を含み、ポリマー鎖は前記第1の断片に結合 し、そして検出できるレポーター標識は前記第2の断片に結合しており、(ii )プローブを標的ポリヌクレオチドと、標的ポリヌクレオチド中のそれらの特異 的標的シーケンスに前記第1と第2の断片を結合するために有効な条件下に反応 させ、(iii)ハイブリッド形成したプローブをRNA/DNA基体に対して 特異的なRNase酵素と反応させて、ポリマー鎖を欠いている修飾した標識プ ローブを形成し、そして(iv)修飾していないまたは修飾した両方の標識プロ ーブを、標的ポリヌクレオチドから脱離して前記異なるシーケンスのポリヌクレ オチドを形成する工程を含む、請求項1の方法。
- 14.複数のシーケンス特異的プローブを含み、各々は(a)選択された結合条 件下に、標的シーケンスの1つにポリマーを塩基特異的に結合するために設計さ れたサブユニットのプローブ特異的シーケンスをもつ結合ポリマー、および(b )結合ポリマーに結合し、結合ポリマーの電荷/並進摩擦抵抗の比とは異なる比 をもつポリマー鎖によって特徴づけられて成る、標的ポリヌクレオチドにおける 複数の異なるシーケンスの1またはそれ以上を検出する際に使用するためのプロ ーブ構成物。
- 15.前記ポリマー鎖は、ポリエチレンオキシド、ポリグリコール酸、ポリ乳酸 、ポリペプチド、オリゴ糖、およびポリウレタン、ポリアミド、ポリスルホンア ミド、ポリスルホキシド、およびそれらのブロックコポリマー、荷電または非荷 電連結基によって連結された多数のサブユニットのユニットから成るポリマーを 含む、から成る群から選ばれる、請求項14の方法。
- 16.各シーケンス特異的プローブがさらにレポーターを有する第2の結合ポリ マーを含み、シーケンス特異的プローブ中の上記第1および第2の結合ポリマー は、選ばれた標的シーケンスの隣接し接触する領域に塩基特異的方法で結合する ために有効であり、シーケンス特異的方法で標的シーケンスに結合したとき2つ の結合ポリマーを連結させ、そして第1の結合ポリマーに結合したポリマー鎖が 各連結したプローブ対に、電荷/並進摩擦抵抗の合わさった特有の比を与える、 請求項14記載の構成物。
- 17.各シーケンス特異的プローブがさらに第2の結合ポリマーを含み、シーケ ンス特異的プローブ中の上記第1および第2の結合ポリマーは、選ばれた2本鎖 の標的シーケンスの向い合った鎖の向い合った末端領域に塩基特異的方法で結合 するために有効であり、各鎖中の標的領域の重合をプライマーに開始させ、そし て第1の結合ポリマーに結合したポリマー鎖が各重合した領域に、電荷/並進摩 擦抵抗の合わさった特有の比を与える、請求項14記載の構成物。
- 18.各シーケンス特異的プローブが、第1の1本鎖DNA断片および1本鎖R NAを含む第2の断片から成る結合ポリマーを含み、ポリマー鎖は前記第1の断 片に結合し、検出できるレポーターは前記第2の断片に結合し、そして各ポリマ ー鎖は前記ポリマー鎖が結合しているプローブに、電荷/並進摩擦抵抗の特有の 比を与える、請求項14記載の構成物。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86264292A | 1992-04-03 | 1992-04-03 | |
| US07/866,018 US5470705A (en) | 1992-04-03 | 1992-04-07 | Probe composition containing a binding domain and polymer chain and methods of use |
| US97311892A | 1992-11-06 | 1992-11-06 | |
| US862,642 | 1992-11-06 | ||
| US866,018 | 1992-11-06 | ||
| US973,118 | 1992-11-06 | ||
| PCT/US1993/003048 WO1993020236A1 (en) | 1992-04-03 | 1993-03-31 | Probe composition and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07505529A true JPH07505529A (ja) | 1995-06-22 |
| JP2775346B2 JP2775346B2 (ja) | 1998-07-16 |
Family
ID=27420419
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5517681A Expired - Fee Related JP2775346B2 (ja) | 1992-04-03 | 1993-03-31 | プローブ構成物および方法 |
| JP5517768A Expired - Fee Related JP2701092B2 (ja) | 1992-04-03 | 1993-04-02 | 異なるdnaシーケンスを検出するためのプローブ方法と構成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5517768A Expired - Fee Related JP2701092B2 (ja) | 1992-04-03 | 1993-04-02 | 異なるdnaシーケンスを検出するためのプローブ方法と構成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US5514543A (ja) |
| EP (2) | EP0636186B1 (ja) |
| JP (2) | JP2775346B2 (ja) |
| AT (2) | ATE173767T1 (ja) |
| DE (2) | DE69322266T2 (ja) |
| DK (1) | DK0635069T3 (ja) |
| WO (2) | WO1993020236A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011754A1 (en) * | 1997-08-29 | 1999-03-11 | Olympus Optical Co., Ltd. | Dna capillary |
| US6559296B2 (en) | 1997-08-29 | 2003-05-06 | Olympus Optical Co., Ltd. | DNA capillary |
Families Citing this family (303)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| ATE173767T1 (de) * | 1992-04-03 | 1998-12-15 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
| US5470705A (en) | 1992-04-03 | 1995-11-28 | Applied Biosystems, Inc. | Probe composition containing a binding domain and polymer chain and methods of use |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| JP3419850B2 (ja) * | 1993-10-26 | 2003-06-23 | 株式会社日立製作所 | 核酸分別方法 |
| US5976798A (en) * | 1994-03-30 | 1999-11-02 | Mitokor | Methods for detecting mitochondrial mutations diagnostic for Alzheimer's disease and methods for determining heteroplasmy of mitochondrial nucleic acid |
| ATE174066T1 (de) * | 1994-04-04 | 1998-12-15 | Ciba Corning Diagnostics Corp | Hybridisation-ligitation-verfahren zum nachweis von spezifischen dns sequenzen |
| US7323298B1 (en) | 1994-06-17 | 2008-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Microarray for determining the relative abundances of polynuceotide sequences |
| US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US7378236B1 (en) | 1994-06-17 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for analyzing gene expression patterns |
| US5849483A (en) * | 1994-07-28 | 1998-12-15 | Ig Laboratories, Inc. | High throughput screening method for sequences or genetic alterations in nucleic acids |
| US5834181A (en) * | 1994-07-28 | 1998-11-10 | Genzyme Corporation | High throughput screening method for sequences or genetic alterations in nucleic acids |
| JP3102800B2 (ja) * | 1994-08-19 | 2000-10-23 | パーキン−エルマー コーポレイション | 増幅及び連結反応の共役法 |
| GB9417211D0 (en) * | 1994-08-25 | 1994-10-12 | Solicitor For The Affairs Of H | Nucleotide sequencing method |
| US5846719A (en) | 1994-10-13 | 1998-12-08 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
| USRE43097E1 (en) | 1994-10-13 | 2012-01-10 | Illumina, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
| US6280935B1 (en) | 1994-10-13 | 2001-08-28 | Lynx Therapeutics, Inc. | Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags |
| US8236493B2 (en) * | 1994-10-21 | 2012-08-07 | Affymetrix, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
| DE19508366C2 (de) * | 1995-03-10 | 1998-01-29 | Evotec Biosystems Gmbh | Verfahren zum direkten Nachweisen weniger Nucleinsäurestränge |
| US5630924A (en) * | 1995-04-20 | 1997-05-20 | Perseptive Biosystems, Inc. | Compositions, methods and apparatus for ultrafast electroseparation analysis |
| US5830655A (en) | 1995-05-22 | 1998-11-03 | Sri International | Oligonucleotide sizing using cleavable primers |
| EP0832287B1 (en) * | 1995-06-07 | 2007-10-10 | Solexa, Inc | Oligonucleotide tags for sorting and identification |
| US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
| US6027890A (en) * | 1996-01-23 | 2000-02-22 | Rapigene, Inc. | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
| US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| US6706471B1 (en) | 1996-01-24 | 2004-03-16 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US6852487B1 (en) | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| US6020481A (en) * | 1996-04-01 | 2000-02-01 | The Perkin-Elmer Corporation | Asymmetric benzoxanthene dyes |
| EP1736554B1 (en) * | 1996-05-29 | 2013-10-09 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US6780982B2 (en) | 1996-07-12 | 2004-08-24 | Third Wave Technologies, Inc. | Charge tags and the separation of nucleic acid molecules |
| JP4000605B2 (ja) | 1996-07-24 | 2007-10-31 | 株式会社日立製作所 | Dna試料調整装置及びこれを用いる電気泳動分析装置 |
| WO1998010097A2 (en) * | 1996-09-03 | 1998-03-12 | Pioneer Hi-Bred International, Inc. | Method and apparatus for single molecule two color fluorescent detection and molecular weight and concentration determination |
| DE69738206T2 (de) | 1996-11-06 | 2008-07-17 | Sequenom, Inc., San Diego | DNA-Diagnostik mittels Massenspektrometrie |
| US6133436A (en) * | 1996-11-06 | 2000-10-17 | Sequenom, Inc. | Beads bound to a solid support and to nucleic acids |
| DE69735445T2 (de) | 1996-12-10 | 2006-08-10 | Sequenom, Inc., San Diego | Abspaltbare, nicht-flüchtige moleküle zur massenmarkierung |
| US6299881B1 (en) * | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US20020015997A1 (en) * | 1997-06-16 | 2002-02-07 | Lafferty William Michael | Capillary array-based sample screening |
| US20030013115A1 (en) * | 1997-06-16 | 2003-01-16 | Diversa Corporation, A Delaware Corporation | Capillary array-based sample screening |
| US6008379A (en) | 1997-10-01 | 1999-12-28 | The Perkin-Elmer Corporation | Aromatic-substituted xanthene dyes |
| US5936087A (en) | 1997-11-25 | 1999-08-10 | The Perkin-Elmer Corporation | Dibenzorhodamine dyes |
| US6583168B1 (en) | 1997-11-25 | 2003-06-24 | Applera Corporation | Sulfonated diarylrhodamine dyes |
| US6087102A (en) | 1998-01-07 | 2000-07-11 | Clontech Laboratories, Inc. | Polymeric arrays and methods for their use in binding assays |
| AU3463699A (en) * | 1998-04-03 | 1999-10-25 | Phylos, Inc. | Addressable protein arrays |
| US6096875A (en) | 1998-05-29 | 2000-08-01 | The Perlein-Elmer Corporation | Nucleotide compounds including a rigid linker |
| US6552167B1 (en) * | 1998-08-28 | 2003-04-22 | Gryphon Therapeutics, Inc. | Polyamide chains of precise length |
| US6238565B1 (en) * | 1998-09-16 | 2001-05-29 | Varian, Inc. | Monolithic matrix for separating bio-organic molecules |
| US7135284B1 (en) * | 1999-02-05 | 2006-11-14 | Integrated Dna Technologies, Inc. | Primer extension methods for production of high specific activity nucleic acid probes |
| US6635419B1 (en) | 1999-02-16 | 2003-10-21 | Applera Corporation | Polynucleotide sequencing method |
| US6395486B1 (en) | 1999-03-15 | 2002-05-28 | Applera Corporation | Probe/mobility modifier complexes for multiplexnucleic acid detection |
| US6506594B1 (en) | 1999-03-19 | 2003-01-14 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| US7014994B1 (en) | 1999-03-19 | 2006-03-21 | Cornell Research Foundation,Inc. | Coupled polymerase chain reaction-restriction-endonuclease digestion-ligase detection reaction process |
| US6514700B1 (en) * | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
| US20040248150A1 (en) * | 1999-04-02 | 2004-12-09 | Sharat Singh | Methods employing oligonucleotide-binding e-tag probes |
| US6322980B1 (en) * | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
| US6627400B1 (en) | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
| US6673550B2 (en) | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
| US6649351B2 (en) | 1999-04-30 | 2003-11-18 | Aclara Biosciences, Inc. | Methods for detecting a plurality of analytes by mass spectrometry |
| US7001725B2 (en) | 1999-04-30 | 2006-02-21 | Aclara Biosciences, Inc. | Kits employing generalized target-binding e-tag probes |
| US20030235832A1 (en) * | 2000-06-21 | 2003-12-25 | Ahmed Chenna | Multiplexed analysis by chromatographic separation of molecular tags |
| US7037654B2 (en) | 1999-04-30 | 2006-05-02 | Aclara Biosciences, Inc. | Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents |
| DE19924606A1 (de) * | 1999-05-28 | 2000-11-30 | Graffinity Pharm Design Gmbh | Ligand-Anker-Konjugate |
| US20020045182A1 (en) * | 1999-07-16 | 2002-04-18 | Lynx Therapeutics, Inc. | Multiplexed differential displacement for nucleic acid determinations |
| EP1136568A4 (en) * | 1999-10-04 | 2004-12-15 | Olympus Optical Corp Ltd | METHOD FOR DETERMINING NUCLEIC ACID |
| US7332275B2 (en) | 1999-10-13 | 2008-02-19 | Sequenom, Inc. | Methods for detecting methylated nucleotides |
| EP1136569A3 (en) | 2000-03-24 | 2004-01-28 | Bayer Corporation | Nucleic acid probes having highly hydrophilic non-nucleosidic tags with multiple labels, and uses thereof |
| EP1303639A2 (en) | 2000-04-14 | 2003-04-23 | Cornell Research Foundation, Inc. | Method of designing addressable array for detection of nucleic acid sequence differences using ligase detection reaction |
| US6329801B1 (en) * | 2000-04-24 | 2001-12-11 | Volterra Semiconductor Corporation | Switching regulator control system and method |
| US20030207300A1 (en) * | 2000-04-28 | 2003-11-06 | Matray Tracy J. | Multiplex analytical platform using molecular tags |
| US20040067498A1 (en) * | 2000-04-28 | 2004-04-08 | Ahmed Chenna | Detection of nucleic acid sequences by cleavage and separation of tag-containing structures |
| US7771929B2 (en) * | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
| US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
| US7160735B2 (en) * | 2000-04-28 | 2007-01-09 | Monogram Biosciences, Inc. | Tagged microparticle compositions and methods |
| US20030170734A1 (en) * | 2000-04-28 | 2003-09-11 | Stephen Williams | Multiplexed assays using electrophoretically separated molecular tags |
| US6743640B2 (en) * | 2000-05-08 | 2004-06-01 | Qtl Biosystems Llc | Fluorescent polymer-QTL approach to biosensing |
| EP1313880A2 (en) * | 2000-05-30 | 2003-05-28 | PE Corporation (NY) | Methods for detecting target nucleic acids using coupled ligation and amplification |
| US6887664B2 (en) | 2000-06-06 | 2005-05-03 | Applera Corporation | Asynchronous primed PCR |
| US6632606B1 (en) | 2000-06-12 | 2003-10-14 | Aclara Biosciences, Inc. | Methods for single nucleotide polymorphism detection |
| US6958214B2 (en) | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
| FR2812658B1 (fr) * | 2000-08-01 | 2005-04-15 | De Bruno Vandiere | Procede d'analyse d'acides nucleiques |
| WO2002029109A2 (en) * | 2000-10-05 | 2002-04-11 | Aclara Biosciences, Inc. | Multiplexed differential displacement for nucleic acid determinations |
| JP2005501217A (ja) * | 2000-10-10 | 2005-01-13 | ディベルサ コーポレーション | 生体活性または生体分子のハイスループットスクリーニングまたはキャピラリーに基づくスクリーニング |
| AU1312502A (en) * | 2000-10-11 | 2002-04-22 | Pe Corp Ny | Fluorescent nucleobase conjugates having anionic linkers |
| EP1363961B1 (en) * | 2001-02-02 | 2009-04-29 | Allvivo, Inc. | End group activated polymers with oligonucleotide ligands |
| WO2002073158A2 (en) * | 2001-03-09 | 2002-09-19 | Apollo Biotechnology, Inc. | Conjugate probes and optical detection of analytes |
| CA2443999A1 (en) * | 2001-04-16 | 2002-10-24 | Applera Corporation | Methods and compositions for nucleotide analysis |
| US6743905B2 (en) * | 2001-04-16 | 2004-06-01 | Applera Corporation | Mobility-modified nucleobase polymers and methods of using same |
| WO2002094998A2 (en) | 2001-05-21 | 2002-11-28 | Aclara Biosciences, Inc. | Analyzing phosphorylated proteins |
| PL373962A1 (en) * | 2001-05-21 | 2005-09-19 | Aclara Biosciences, Inc. | Methods and compositions for analyzing proteins |
| WO2002097112A2 (en) * | 2001-05-26 | 2002-12-05 | Aclara Biosciences, Inc. | Catalytic amplification of multiplexed assay signals |
| CA2463420A1 (en) * | 2001-10-24 | 2003-05-01 | Singulex, Inc. | Methods for detecting genetic haplotypes by interaction with probes |
| US7045311B2 (en) * | 2001-10-25 | 2006-05-16 | Monogram Biosciences, Inc. | Whole cell assay systems for cell surface proteases |
| CN1166422C (zh) * | 2001-11-05 | 2004-09-15 | 北京源德生物医学工程股份有限公司 | 用于体外高能聚焦超声波治疗机的坐位架 |
| US20030162202A1 (en) * | 2001-11-09 | 2003-08-28 | Becker Kenneth David | Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin |
| US20040067512A1 (en) * | 2001-11-09 | 2004-04-08 | Neurogenetics, Inc. | Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin |
| US20050053939A1 (en) * | 2001-11-09 | 2005-03-10 | Ahmed Chenna | Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents |
| AU2002362013B2 (en) | 2001-11-21 | 2008-04-24 | Applied Biosystems, Llc. | Digital assay |
| EP1465998A2 (en) | 2002-01-08 | 2004-10-13 | Bayer HealthCare AG | Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy |
| US6949347B2 (en) * | 2002-03-05 | 2005-09-27 | Aclara Biosciences, Inc. | Multiplex analysis using membrane-bound sensitizers |
| US20030177380A1 (en) * | 2002-03-18 | 2003-09-18 | Woods Stanley P. | Devices for storing array data and methods of using the same |
| JP2003294742A (ja) * | 2002-03-29 | 2003-10-15 | Inst Of Physical & Chemical Res | ハイブリダイゼーション用基板及びその使用方法 |
| AU2003228809A1 (en) | 2002-05-03 | 2003-11-17 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof, and related methods |
| US7402397B2 (en) * | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| US20040229293A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | Surface receptor complexes as biomarkers |
| US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
| US20040229299A1 (en) * | 2002-05-21 | 2004-11-18 | Badal M. Youssouf | Intracellular complexes as biomarkers |
| US20040175765A1 (en) * | 2002-07-05 | 2004-09-09 | Sharat Singh | Cell-screening assay and composition |
| JP4443407B2 (ja) | 2002-07-25 | 2010-03-31 | アクララ バイオサイエンシーズ, インコーポレイテッド | レセプターオリゴマー形成の検出 |
| JP2005534686A (ja) | 2002-07-31 | 2005-11-17 | ユニバーシティ オブ サザン カリフォルニア | 疾患および処置結果の予見のための多型性 |
| US7381317B2 (en) | 2002-08-12 | 2008-06-03 | Beckman Coulter, Inc. | Methods and compositions for capillary electrophoresis (CE) |
| US7153658B2 (en) | 2002-09-19 | 2006-12-26 | Applera Corporation | Methods and compositions for detecting targets |
| US20040235005A1 (en) * | 2002-10-23 | 2004-11-25 | Ernest Friedlander | Methods and composition for detecting targets |
| US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
| CA2505687A1 (en) * | 2002-11-19 | 2004-06-03 | Applera Corporation | Polynucleotide sequence detection assays and analysis |
| WO2005005666A1 (en) * | 2002-11-19 | 2005-01-20 | Singulex, Inc. | Detection of target molecules through interaction with probes |
| US20050053957A1 (en) * | 2002-11-19 | 2005-03-10 | Applera Corporation | Polynucleotide sequence detection assays |
| WO2005001129A2 (en) * | 2003-06-06 | 2005-01-06 | Applera Corporation | Mobility cassettes |
| US7402398B2 (en) * | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| WO2005019419A2 (en) * | 2003-07-31 | 2005-03-03 | Singulex, Inc. | Co-detection of single polypeptide and polynucleotide molecules |
| WO2005019470A2 (en) * | 2003-08-11 | 2005-03-03 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| WO2005028629A2 (en) * | 2003-09-19 | 2005-03-31 | Applera Corporation | Whole genome expression analysis system |
| US7570443B2 (en) | 2003-09-19 | 2009-08-04 | Applied Biosystems, Llc | Optical camera alignment |
| CA2543830A1 (en) * | 2003-10-27 | 2005-05-19 | Monogram Biosciences, Inc. | Detecting human anti-therapeutic antibodies |
| US20050094807A1 (en) * | 2003-11-04 | 2005-05-05 | John Silzel | Accuracy array assay system and method |
| JP2007517511A (ja) * | 2004-01-10 | 2007-07-05 | バイエル・ヘルスケア・エルエルシー | ヒトチオプリンs−メチルトランスフェラーゼ欠損に関連するハプロタイプおよび多型 |
| ATE399884T1 (de) * | 2004-03-24 | 2008-07-15 | Applera Corp | Codierungs- und decodierungsreaktionen zur bestimmung von target-polynukleotiden |
| US20050255485A1 (en) * | 2004-05-14 | 2005-11-17 | Livak Kenneth J | Detection of gene duplications |
| EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US20060003337A1 (en) * | 2004-06-30 | 2006-01-05 | John Brandis | Detection of small RNAS |
| US20060115827A1 (en) | 2004-07-01 | 2006-06-01 | University Of Southern California | Genetic markers for predicting disease and treatment outcome |
| CA2857881A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| WO2006076650A2 (en) * | 2005-01-12 | 2006-07-20 | Applera Corporation | Compositions, methods, and kits for selective amplification of nucleic acids |
| EP2604703B1 (en) | 2005-03-14 | 2017-02-01 | The Board of Trustees of the Leland Stanford Junior University | Methods for evaluating graft survival in a solid organ transplant recipient |
| WO2006099604A2 (en) * | 2005-03-16 | 2006-09-21 | Compass Genetics, Llc | Methods and compositions for assay readouts on multiple analytical platforms |
| EP2409980B1 (en) | 2005-04-14 | 2015-06-03 | Applied Biosystems, LLC | 3'modified oligonucleotides containing pseudoisocytosine nucleobase derivatives and applications thereof as primers or probes |
| EP1731620A1 (en) | 2005-06-07 | 2006-12-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for the diagnosis of immune graft tolerance |
| US20070087360A1 (en) * | 2005-06-20 | 2007-04-19 | Boyd Victoria L | Methods and compositions for detecting nucleotides |
| US20070014699A1 (en) | 2005-06-23 | 2007-01-18 | Beckman Coulter, Inc, | Methods and apparatus for improving the sensitivity of capillary zone electrophoresis |
| WO2007011867A2 (en) * | 2005-07-15 | 2007-01-25 | Applera Corporation | Fluid processing device and method |
| US20070099211A1 (en) * | 2005-07-15 | 2007-05-03 | Vissarion Aivazachvili | Detection of nucleic acid amplification |
| WO2007039147A1 (en) | 2005-09-22 | 2007-04-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of using il-21 |
| US20070202515A1 (en) * | 2005-10-12 | 2007-08-30 | Pathologica, Llc. | Promac signature application |
| US7807364B2 (en) | 2006-03-03 | 2010-10-05 | University Of Southern California | Angiogenesis pathway gene polymorphisms for therapy selection |
| US20070215472A1 (en) * | 2006-03-15 | 2007-09-20 | Slater Gary W | Electroosmotic flow for end labelled free solution electrophoresis |
| US20070218494A1 (en) * | 2006-03-17 | 2007-09-20 | Gary Slater | Branched polymer lables as drag-tags in free solution electrophoresis |
| US7759062B2 (en) * | 2006-06-09 | 2010-07-20 | Third Wave Technologies, Inc. | T-structure invasive cleavage assays, consistent nucleic acid dispensing, and low level target nucleic acid detection |
| EP3796002B1 (en) | 2006-07-14 | 2023-11-22 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
| WO2008036765A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| JP2010510964A (ja) | 2006-09-19 | 2010-04-08 | アシュラジェン インコーポレイテッド | 治療的介入の標的としての、miR−15、miR−26、miR−31、miR−145、miR−147、miR−188、miR−215、miR−216、miR−331、mmu−miR−292−3pによって調節される遺伝子および経路 |
| WO2008076842A2 (en) * | 2006-12-14 | 2008-06-26 | Applied Biosystems Inc. | Sequencing methods |
| US8114599B2 (en) | 2006-12-19 | 2012-02-14 | Northwestern University | Compositions and methods for free-solution conjugate nucleic acid analysis |
| WO2008088860A2 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Polymorphisms in the egfr pathway as markers for cancer treatment |
| AU2008205457A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual TKI therapy |
| EP2993473A1 (en) | 2007-01-30 | 2016-03-09 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
| FI20075124A0 (fi) * | 2007-02-21 | 2007-02-21 | Valtion Teknillinen | Menetelmä ja testikitti nukleotidivariaatioiden toteamiseksi |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| ES2426814T3 (es) | 2007-03-13 | 2013-10-25 | Amgen Inc. | Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr |
| AR065687A1 (es) | 2007-03-13 | 2009-06-24 | Amgen Inc | Metodo para determinar la presencia o no de una mutacion k-ras y terapia con anticuerpos anti-egfr |
| EP3543357A1 (en) | 2007-05-08 | 2019-09-25 | Trustees of Boston University | Chemical functionalization of solid-state nanopores and nanopore arrays and applications thereof |
| US8008010B1 (en) | 2007-06-27 | 2011-08-30 | Applied Biosystems, Llc | Chimeric oligonucleotides for ligation-enhanced nucleic acid detection, methods and compositions therefor |
| US8357277B2 (en) * | 2007-11-27 | 2013-01-22 | Laboratory Corp. of America Holdings | Enhanced method for detecting and/or quantifying an analyte in a sample |
| WO2009097424A1 (en) * | 2008-01-29 | 2009-08-06 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fstl-1 as a biomarker of inflammation |
| US8658379B2 (en) | 2008-01-29 | 2014-02-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | Follistatin-like protein-1 as a biomarker for sepsis |
| EP2113574A1 (en) | 2008-04-28 | 2009-11-04 | Biotype AG | Substances and methods for a DNA based profiling assay |
| US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
| US20110111417A1 (en) | 2008-05-14 | 2011-05-12 | Millennium Pharmaceuticals, Inc. | Methods and kits for monitoring the effects of immunomodulators on adaptive immunity |
| WO2009145802A1 (en) * | 2008-05-30 | 2009-12-03 | The Trustess Of Columbia University In The City Of New York | Systems and methods for integrating a single dna molecule into a molecular electronic device |
| US8208909B2 (en) | 2008-06-02 | 2012-06-26 | West Corporation | System, apparatus and method for availing a mobile call of address information |
| WO2010021696A1 (en) | 2008-08-18 | 2010-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for determining a graft tolerant phenotype in a subject |
| WO2010065517A1 (en) | 2008-12-01 | 2010-06-10 | The Trustees Of Columbia University In The City Of New York | Electromechanical devices and methods for fabrication of the same |
| DE102009010563A1 (de) | 2009-02-16 | 2010-08-26 | Matthias W. Engel | Vorrichtung zum Nachweis von Analyten in Körperflüssigkeiten |
| WO2010123625A1 (en) | 2009-04-24 | 2010-10-28 | University Of Southern California | Cd133 polymorphisms predict clinical outcome in patients with cancer |
| WO2011004345A1 (en) | 2009-07-09 | 2011-01-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Upstream binding protein 1 polymorphisms and their use for prognosing or diagnosing arterial blood pressure |
| CN104293646A (zh) | 2009-08-22 | 2015-01-21 | 里兰斯坦福初级大学理事会 | 成像并评估胚胎、卵母细胞和干细胞 |
| AU2010301128B2 (en) | 2009-09-30 | 2014-09-18 | Quantapore, Inc. | Ultrafast sequencing of biological polymers using a labeled nanopore |
| US20120316187A1 (en) | 2009-11-13 | 2012-12-13 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| US9290813B2 (en) | 2009-12-02 | 2016-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers for determining an allograft tolerant phenotype |
| GB0922085D0 (en) | 2009-12-17 | 2010-02-03 | Cambridge Entpr Ltd | Cancer diagnosis and treatment |
| US20120288861A1 (en) | 2009-12-21 | 2012-11-15 | Heinz-Josef Lenz | Germline polymorphisms in the sparc gene associated with clinical outcome in gastric cancer |
| WO2011085334A1 (en) | 2010-01-11 | 2011-07-14 | University Of Southern California | Cd44 polymorphisms predict clinical outcome in patients with gastric cancer |
| TWI518325B (zh) | 2010-02-04 | 2016-01-21 | 自治醫科大學 | 對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療 |
| ES2631458T3 (es) | 2010-03-04 | 2017-08-31 | Interna Technologies B.V. | Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT |
| EP2561092A1 (en) | 2010-04-19 | 2013-02-27 | The Procter & Gamble Company | Genetic signatures and gene chips associated with administration of electrically conducted radio frequency current to skin and methods and treatments relating thereto |
| JP2013524946A (ja) | 2010-04-19 | 2013-06-20 | ザ プロクター アンド ギャンブル カンパニー | 哺乳類の皮膚の状態を調節するための、エネルギー及び局所適用組成物の併用 |
| WO2011139721A1 (en) | 2010-04-27 | 2011-11-10 | The Regents Of The University Of California | Cancer biomarkers and methods of use thereof |
| WO2011143556A1 (en) * | 2010-05-13 | 2011-11-17 | Gen9, Inc. | Methods for nucleotide sequencing and high fidelity polynucleotide synthesis |
| WO2011146725A1 (en) | 2010-05-19 | 2011-11-24 | Bayer Healthcare Llc | Biomarkers for a multikinase inhibitor |
| US8586301B2 (en) | 2010-06-30 | 2013-11-19 | Stratos Genomics, Inc. | Multiplexed identification of nucleic acid sequences |
| NZ704322A (en) | 2010-07-06 | 2016-07-29 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| WO2012019099A2 (en) | 2010-08-05 | 2012-02-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Follistatin-like-protein-1 as a biomarker for inflammatory disorders |
| CA2811015A1 (en) | 2010-09-15 | 2012-03-22 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| WO2012051301A1 (en) | 2010-10-12 | 2012-04-19 | President And Fellows Of Harvard College | Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism |
| EP2772550B1 (en) | 2010-11-17 | 2017-03-29 | Interpace Diagnostics, LLC | Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms |
| EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| US8486717B2 (en) | 2011-01-18 | 2013-07-16 | Symbolics, Llc | Lateral flow assays using two dimensional features |
| EP2678675B1 (en) | 2011-02-23 | 2017-10-11 | The Board of Trustees of the Leland Stanford Junior University | Methods of detecting aneuploidy in human embryos |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| EP2681566A2 (en) | 2011-02-28 | 2014-01-08 | University of Iowa Research Foundation | Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender |
| JP6040227B2 (ja) | 2011-05-19 | 2016-12-07 | アジーナ バイオサイエンス, インコーポレイテッド | マルチプレックス核酸同定のための製品およびプロセス |
| BR112013031019A2 (pt) | 2011-06-02 | 2017-03-21 | Almac Diagnostics Ltd | teste diagnóstico molecular para câncer |
| WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
| WO2013063519A1 (en) | 2011-10-26 | 2013-05-02 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
| WO2013063544A1 (en) | 2011-10-27 | 2013-05-02 | Asuragen, Inc. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
| EP2771489B1 (en) | 2011-10-28 | 2018-07-04 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to nae inhibitors |
| CN104039328B (zh) | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
| CA2855368A1 (en) | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| WO2013087789A1 (en) | 2011-12-13 | 2013-06-20 | Glykos Finland Ltd. | Antibody isoform arrays and methods thereof |
| EP2870263A1 (en) | 2012-07-03 | 2015-05-13 | InteRNA Technologies B.V. | Diagnostic portfolio and its uses |
| US9695416B2 (en) | 2012-07-18 | 2017-07-04 | Siemens Healthcare Diagnostics Inc. | Method of normalizing biological samples |
| US9874556B2 (en) | 2012-07-18 | 2018-01-23 | Symbolics, Llc | Lateral flow assays using two dimensional features |
| EP3418395A1 (en) | 2012-09-06 | 2018-12-26 | Life Technologies Corporation | Multiplex y-str analysis |
| WO2014055543A2 (en) | 2012-10-01 | 2014-04-10 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
| WO2014055117A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
| US10206911B2 (en) | 2012-10-26 | 2019-02-19 | Memorial Sloan-Kettering Cancer Center | Androgen receptor variants and methods for making and using |
| US9651539B2 (en) | 2012-10-28 | 2017-05-16 | Quantapore, Inc. | Reducing background fluorescence in MEMS materials by low energy ion beam treatment |
| ME02925B (me) | 2012-11-28 | 2018-04-20 | Merck Sharp & Dohme | Kompozicije i postupci za liječenje kancera |
| MX2015006955A (es) | 2012-12-03 | 2016-01-25 | Almac Diagnostics Ltd | Prueba de diagnostico molecular para cancer. |
| WO2014144666A2 (en) | 2013-03-15 | 2014-09-18 | The University Of Chicago | Methods and compositions related to t-cell activity |
| EP2971149B1 (en) | 2013-03-15 | 2018-05-09 | Baylor Research Institute | Ulcerative colitis (uc)-associated colorectal neoplasia markers |
| EP2971132B1 (en) | 2013-03-15 | 2020-05-06 | Baylor Research Institute | Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer |
| EP2805769A1 (en) | 2013-05-24 | 2014-11-26 | European Molecular Biology Laboratory | Methods for nano-scale single cell analysis |
| WO2014190322A2 (en) | 2013-05-24 | 2014-11-27 | Quantapore, Inc. | Nanopore-based nucleic acid analysis with mixed fret detection |
| US9670545B2 (en) | 2013-06-11 | 2017-06-06 | Coutagen Life Sciences, Inc. | Methods and kits for treating and classifying individuals at risk of or suffering from TRAP1 change-of-function |
| TWI707038B (zh) | 2013-08-05 | 2020-10-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| EP3044592B1 (en) | 2013-09-13 | 2019-07-17 | Symbolics, LLC | Lateral flow assays using two dimensional test and control signal readout patterns |
| WO2015094992A1 (en) | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
| GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| US10328062B2 (en) | 2014-04-04 | 2019-06-25 | Amgen, Inc. | Biomarkers and use of MET inhibitor for treatment of cancer |
| EP3194623B1 (en) | 2014-08-12 | 2022-01-05 | Wayne State University | Systems and methods to detect stem cell stress and uses thereof |
| ES2789000T3 (es) | 2014-10-10 | 2020-10-23 | Quantapore Inc | Análisis de polinucleótidos basado en nanoporos con marcadores fluorescentes que se inactivan mutuamente |
| GB201418892D0 (en) * | 2014-10-23 | 2014-12-10 | Proqr Therapeutics B V | DNA editing |
| US9624537B2 (en) | 2014-10-24 | 2017-04-18 | Quantapore, Inc. | Efficient optical analysis of polymers using arrays of nanostructures |
| WO2016090323A1 (en) | 2014-12-05 | 2016-06-09 | Prelude, Inc. | Dcis recurrence and invasive breast cancer |
| EP3230498B1 (en) | 2014-12-09 | 2023-01-18 | Merck Sharp & Dohme LLC | System and methods for deriving gene signature biomarkers of response to pd-1 antagonists |
| CA2975855C (en) | 2015-02-04 | 2025-09-23 | Twist Bioscience Corporation | SYNTHETIC GENE COMPOSITIONS AND ASSEMBLY METHODS |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016168133A1 (en) | 2015-04-17 | 2016-10-20 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| US10640817B2 (en) | 2015-04-24 | 2020-05-05 | Agena Bioscience, Inc. | Multiplex methods for detection and quantification of minor variants |
| WO2016172571A1 (en) | 2015-04-24 | 2016-10-27 | Agena Bioscience, Inc. | Multiplexed method for the identification and quantitation of minor alleles and polymorphisms |
| GB201512869D0 (en) | 2015-07-21 | 2015-09-02 | Almac Diagnostics Ltd | Gene signature for minute therapies |
| KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
| KR102794025B1 (ko) | 2015-09-22 | 2025-04-09 | 트위스트 바이오사이언스 코포레이션 | 핵산 합성을 위한 가요성 기판 |
| CN115920796A (zh) | 2015-12-01 | 2023-04-07 | 特韦斯特生物科学公司 | 功能化表面及其制备 |
| CN109073654A (zh) | 2016-04-20 | 2018-12-21 | 苏州爱尔迪思生物科技有限公司 | 用于预测早产的方法和组合物 |
| CN109196362A (zh) | 2016-05-17 | 2019-01-11 | 苏州爱尔迪思生物科技有限公司 | 用于提供子痫前期评估的方法和组合物 |
| US10823721B2 (en) | 2016-07-05 | 2020-11-03 | Quantapore, Inc. | Optically based nanopore sequencing |
| JP6854340B2 (ja) | 2016-08-22 | 2021-04-07 | ツイスト バイオサイエンス コーポレーション | デノボ合成された核酸ライブラリ |
| US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
| KR102514213B1 (ko) | 2016-12-16 | 2023-03-27 | 트위스트 바이오사이언스 코포레이션 | 면역 시냅스의 변이체 라이브러리 및 그의 합성 |
| CN110892485B (zh) | 2017-02-22 | 2024-03-22 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| WO2018170169A1 (en) | 2017-03-15 | 2018-09-20 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| WO2018186947A1 (en) * | 2017-04-06 | 2018-10-11 | MyOmicsDx, Inc | Method and kit for targeted enrichment of nucleic acids |
| CN110719958B (zh) * | 2017-04-06 | 2023-07-18 | 康博国际有限公司 | 构建核酸文库的方法和试剂盒 |
| US12310999B2 (en) | 2017-04-28 | 2025-05-27 | Merck Sharp & Dohme Corp. | Biomarkers for cancer therapeutics |
| US10696965B2 (en) | 2017-06-12 | 2020-06-30 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| CN111566125A (zh) | 2017-09-11 | 2020-08-21 | 特韦斯特生物科学公司 | Gpcr结合蛋白及其合成 |
| CN111565834B (zh) | 2017-10-20 | 2022-08-26 | 特韦斯特生物科学公司 | 用于多核苷酸合成的加热的纳米孔 |
| US11497762B2 (en) | 2017-11-03 | 2022-11-15 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
| EP3714053B1 (en) | 2017-11-22 | 2025-12-31 | The University of Chicago | CHEMICALLY DEPENDENT PROBE EVALUATION OF PROTEIN ACTIVITY AND ITS USES |
| WO2019109016A1 (en) | 2017-12-01 | 2019-06-06 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods for treatment with nae inhibitors |
| KR102804057B1 (ko) | 2018-01-04 | 2025-05-07 | 트위스트 바이오사이언스 코포레이션 | Dna 기반 디지털 정보 저장 |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| US20210386829A1 (en) | 2018-05-04 | 2021-12-16 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| WO2020036926A1 (en) | 2018-08-17 | 2020-02-20 | Cellecta, Inc. | Multiplex preparation of barcoded gene specific dna fragments |
| WO2020056338A1 (en) | 2018-09-14 | 2020-03-19 | Prelude Corporation | Method of selection for treatment of subjects at risk of invasive breast cancer |
| US20220401460A1 (en) | 2018-10-10 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Modulating resistance to bcl-2 inhibitors |
| US12402610B2 (en) | 2018-11-09 | 2025-09-02 | The Broad Institute, Inc. | Methods and compositions for modulating innate lymphoid cell pathogenic effectors |
| US12357959B2 (en) | 2018-12-26 | 2025-07-15 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| CA3131691A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| CN113766930B (zh) | 2019-02-26 | 2025-07-22 | 特韦斯特生物科学公司 | Glp1受体的变异核酸文库 |
| AU2020228047B2 (en) | 2019-02-27 | 2025-11-20 | Madera Therapeutics, LLC | Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| WO2020186235A1 (en) | 2019-03-14 | 2020-09-17 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells |
| US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| US20220152148A1 (en) | 2019-03-18 | 2022-05-19 | The Broad Institute, Inc. | Modulation of type 2 immunity by targeting clec-2 signaling |
| CN114174532A (zh) | 2019-04-05 | 2022-03-11 | 德克萨斯大学系统董事会 | 细胞条形码编码的方法和应用 |
| WO2020210521A2 (en) | 2019-04-12 | 2020-10-15 | The Regents Of The University Of California | Compositions and methods for increasing muscle mass and oxidative metabolism |
| AU2020298294A1 (en) | 2019-06-21 | 2022-02-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| CN110470760A (zh) * | 2019-08-16 | 2019-11-19 | 谱尼测试集团吉林有限公司 | 塑料制品中聚乳酸含量的检测方法 |
| JP2022548309A (ja) | 2019-09-23 | 2022-11-17 | ツイスト バイオサイエンス コーポレーション | Crth2のバリアント核酸ライブラリー |
| WO2021061842A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for single domain antibodies |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
| IL293670A (en) | 2019-12-09 | 2022-08-01 | Twist Bioscience Corp | Variable nucleic acid libraries for adenosine receptors |
| US20230044602A1 (en) | 2019-12-20 | 2023-02-09 | EDWARD Via COLLEGE OF OSTEOPATHIC MEDICINE | Cancer signatures, methods of generating cancer signatures, and uses thereof |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| WO2022032228A1 (en) | 2020-08-07 | 2022-02-10 | The Broad Institute, Inc. | Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex |
| WO2022192419A2 (en) | 2021-03-09 | 2022-09-15 | Massachusetts Institute Of Technology | Methods of treating inflammatory bowel disease (ibd) with anti- tnf-blockade |
| WO2023158732A1 (en) | 2022-02-16 | 2023-08-24 | Dana-Farber Cancer Institute, Inc. | Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof |
| WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
| WO2024226838A2 (en) | 2023-04-25 | 2024-10-31 | The Brigham And Women's Hospital, Inc. | Treatment of autoimmune diseases having a pathogenic t cell state |
| WO2025240660A1 (en) | 2024-05-15 | 2025-11-20 | Foresite Labs, Llc | Drug development and drug activity determination for coronary artery disease (cad) |
| WO2025248505A1 (en) | 2024-05-31 | 2025-12-04 | Wayne State University | Methods for treating endometrial and ovarian hyperproliferative disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687732A (en) * | 1983-06-10 | 1987-08-18 | Yale University | Visualization polymers and their application to diagnostic medicine |
| US5171534A (en) * | 1984-01-16 | 1992-12-15 | California Institute Of Technology | Automated DNA sequencing technique |
| US4883750A (en) * | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5011769A (en) * | 1985-12-05 | 1991-04-30 | Meiogenics U.S. Limited Partnership | Methods for detecting nucleic acid sequences |
| US5093232A (en) * | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
| US4855225A (en) | 1986-02-07 | 1989-08-08 | Applied Biosystems, Inc. | Method of detecting electrophoretically separated oligonucleotides |
| US4925785A (en) * | 1986-03-07 | 1990-05-15 | Biotechnica Diagnostics, Inc. | Nucleic acid hybridization assays |
| US5525465A (en) * | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| US4879214A (en) * | 1988-11-15 | 1989-11-07 | E. I. Du Pont De Nemours And Company | Differentiation of nucleic acid segments on the basis of nucleotide differences |
| US5061361A (en) * | 1989-03-06 | 1991-10-29 | Hewlett-Packard Company | Capillary zone electrophoresis cell system |
| US5108568A (en) * | 1989-07-07 | 1992-04-28 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells |
| EP0442177B1 (en) * | 1990-02-13 | 1994-03-30 | Bio-Rad Laboratories, Inc. | Electrophoretic sieving in gel-free media with dissolved polymers |
| DE69133629D1 (de) * | 1990-05-03 | 2010-04-15 | Cornell Res Foundation Inc | nssystem zur Bestimmung von genetischen Krankheiten |
| US5096557A (en) * | 1990-07-11 | 1992-03-17 | Genetype A.G. | Internal standard for electrophoretic separations |
| US5677440A (en) * | 1990-07-16 | 1997-10-14 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates |
| WO1992008728A1 (en) * | 1990-11-08 | 1992-05-29 | Hybridon, Inc. | Incorporation of multiple reporter groups on synthetic oligonucleotides |
| US5470705A (en) * | 1992-04-03 | 1995-11-28 | Applied Biosystems, Inc. | Probe composition containing a binding domain and polymer chain and methods of use |
| ATE173767T1 (de) * | 1992-04-03 | 1998-12-15 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
-
1993
- 1993-03-31 AT AT93909463T patent/ATE173767T1/de not_active IP Right Cessation
- 1993-03-31 WO PCT/US1993/003048 patent/WO1993020236A1/en not_active Ceased
- 1993-03-31 JP JP5517681A patent/JP2775346B2/ja not_active Expired - Fee Related
- 1993-03-31 EP EP93909463A patent/EP0636186B1/en not_active Expired - Lifetime
- 1993-03-31 DE DE69322266T patent/DE69322266T2/de not_active Expired - Lifetime
- 1993-04-02 WO PCT/US1993/003229 patent/WO1993020239A1/en not_active Ceased
- 1993-04-02 AT AT93912131T patent/ATE159765T1/de not_active IP Right Cessation
- 1993-04-02 DK DK93912131T patent/DK0635069T3/da active
- 1993-04-02 DE DE69314946T patent/DE69314946T2/de not_active Expired - Lifetime
- 1993-04-02 JP JP5517768A patent/JP2701092B2/ja not_active Expired - Fee Related
- 1993-04-02 EP EP93912131A patent/EP0635069B1/en not_active Expired - Lifetime
- 1993-08-04 US US08/102,372 patent/US5514543A/en not_active Expired - Lifetime
-
1994
- 1994-08-26 US US08/296,880 patent/US5580732A/en not_active Expired - Lifetime
-
1995
- 1995-05-19 US US08/447,174 patent/US5624800A/en not_active Expired - Lifetime
-
1996
- 1996-05-06 US US08/643,709 patent/US5777096A/en not_active Expired - Lifetime
-
1997
- 1997-02-14 US US08/800,641 patent/US5989871A/en not_active Expired - Lifetime
-
2002
- 2002-06-10 US US10/167,337 patent/US6759202B2/en not_active Expired - Fee Related
-
2004
- 2004-04-14 US US10/825,074 patent/US7115376B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011754A1 (en) * | 1997-08-29 | 1999-03-11 | Olympus Optical Co., Ltd. | Dna capillary |
| US6559296B2 (en) | 1997-08-29 | 2003-05-06 | Olympus Optical Co., Ltd. | DNA capillary |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69322266D1 (de) | 1999-01-07 |
| WO1993020239A1 (en) | 1993-10-14 |
| US6759202B2 (en) | 2004-07-06 |
| JP2701092B2 (ja) | 1998-01-21 |
| EP0636186B1 (en) | 1998-11-25 |
| US20050112608A1 (en) | 2005-05-26 |
| DE69314946D1 (de) | 1997-12-04 |
| JPH08504082A (ja) | 1996-05-07 |
| US5624800A (en) | 1997-04-29 |
| US5989871A (en) | 1999-11-23 |
| DK0635069T3 (da) | 1998-07-20 |
| US5777096A (en) | 1998-07-07 |
| US20030073108A1 (en) | 2003-04-17 |
| EP0636186A1 (en) | 1995-02-01 |
| DE69314946T2 (de) | 1998-04-02 |
| US5514543A (en) | 1996-05-07 |
| DE69322266T2 (de) | 1999-06-02 |
| ATE173767T1 (de) | 1998-12-15 |
| WO1993020236A1 (en) | 1993-10-14 |
| EP0635069B1 (en) | 1997-10-29 |
| US7115376B2 (en) | 2006-10-03 |
| JP2775346B2 (ja) | 1998-07-16 |
| ATE159765T1 (de) | 1997-11-15 |
| EP0635069A1 (en) | 1995-01-25 |
| US5580732A (en) | 1996-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07505529A (ja) | プローブ構成物および方法 | |
| US5703222A (en) | Probe composition containing a binding domain and polymer chain and methods of use | |
| US7074569B2 (en) | Mobility-modified nucleobase polymers and methods of using same | |
| JP2788034B2 (ja) | ポリヌクレオチドのアツセイのための増幅方法 | |
| JP3789817B2 (ja) | Pna−dnaキメラプローブを用いたテンプレート依存型ライゲーション | |
| AU770217B2 (en) | Ligation assembly and detection of polynucleotides on solid-support | |
| US6124092A (en) | Multiplex polynucleotide capture methods and compositions | |
| US20030064402A1 (en) | Multipartite high-affinity nucleic acid probes | |
| JP2003507024A (ja) | Pna−dnaキメラの3’末端でのポリメラーゼ伸長 | |
| JPH11504517A (ja) | オリゴヌクレオチドの化学結合による核酸検出及び増幅 | |
| EP0756009A2 (en) | Method for amplification of a base sequence | |
| JP3001919B2 (ja) | 蛍光標識dnaの調製方法及びキット | |
| JP2001518787A (ja) | 核酸ハイブリッド形成検知システムおよびその調製法と応用 | |
| McGuire | Synthesis and studies of modified nucleotides and oligonucleotides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090501 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100501 Year of fee payment: 12 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100501 Year of fee payment: 12 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100501 Year of fee payment: 12 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100501 Year of fee payment: 12 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110501 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110501 Year of fee payment: 13 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110501 Year of fee payment: 13 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110501 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120501 Year of fee payment: 14 |
|
| LAPS | Cancellation because of no payment of annual fees |